UBS Group AG Raises Position in ARS Pharmaceuticals, Inc. $SPRY

UBS Group AG boosted its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 235.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,210,866 shares of the company’s stock after buying an additional 1,550,980 shares during the period. UBS Group AG’s holdings in ARS Pharmaceuticals were worth $25,757,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. lifted its holdings in ARS Pharmaceuticals by 25.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company’s stock worth $56,000 after buying an additional 982 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in ARS Pharmaceuticals by 3.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,994 shares of the company’s stock worth $596,000 after buying an additional 1,234 shares during the period. Belpointe Asset Management LLC lifted its holdings in ARS Pharmaceuticals by 8.9% in the third quarter. Belpointe Asset Management LLC now owns 18,860 shares of the company’s stock worth $190,000 after buying an additional 1,537 shares during the period. Osaic Holdings Inc. lifted its holdings in ARS Pharmaceuticals by 52.8% in the second quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock worth $91,000 after buying an additional 1,803 shares during the period. Finally, CWM LLC lifted its holdings in ARS Pharmaceuticals by 243.7% in the third quarter. CWM LLC now owns 2,547 shares of the company’s stock worth $26,000 after buying an additional 1,806 shares during the period. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on SPRY. Weiss Ratings lowered shares of ARS Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Zacks Research upgraded shares of ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Northland Securities began coverage on shares of ARS Pharmaceuticals in a report on Thursday, April 9th. They issued an “outperform” rating and a $25.00 price objective for the company. Finally, Leerink Partners set a $26.00 target price on shares of ARS Pharmaceuticals and gave the company an “outperform” rating in a research note on Tuesday, March 10th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $28.25.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ SPRY opened at $8.74 on Monday. ARS Pharmaceuticals, Inc. has a fifty-two week low of $6.66 and a fifty-two week high of $18.90. The company has a 50 day simple moving average of $8.41 and a two-hundred day simple moving average of $9.35. The company has a market capitalization of $867.88 million, a price-to-earnings ratio of -4.99 and a beta of 0.93. The company has a debt-to-equity ratio of 1.47, a quick ratio of 7.06 and a current ratio of 7.28.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its earnings results on Monday, March 9th. The company reported ($0.42) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.42). The business had revenue of $28.09 million during the quarter, compared to the consensus estimate of $25.58 million. ARS Pharmaceuticals had a negative net margin of 203.25% and a negative return on equity of 100.29%. Analysts expect that ARS Pharmaceuticals, Inc. will post -1.54 EPS for the current fiscal year.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.